||Human Homo sapiens
||Yewdell JW, Reits E, Neefjes J. Making sense of mass destruction: quantitating MHC class I antigen presentation. Nat Rev Immunol. 2003 Dec3(12):952-61. DOI: 10.1038/nri1250 p.959 left column 2nd paragraphPubMed ID14647477
|| Reits, E. et al. Peptide diffusion, protection, and degradation in nuclear and cytoplasmic compartments before antigen presentation by MHC class I. Immunity 18, 97–108 (2003).PubMed ID12530979
||Primary source p.98 left column bottom paragraph: "To visualize different components of the MHC class I-processing pathway in vivo, the human melanoma cell line Mel JuSo was stably transfected with the proteasomal subunit LMP2 or the TAP subunit TAP1, both tagged with the green fluorescent protein (GFP) and analyzed by confocal microscopy (Reits et al. 1997, Reits et al. 2000)."
||P.959 left column 2nd paragraph: "In vivo peptide-competition experiments indicate an even lower steady-state peptide concentration (2 × 10^5 peptides per cell)[primary source] — a discrepancy that needs to be explored. The rapid peptide turnover protects cells from becoming overwhelmed with oligopeptides (which might be toxic) from the marked protein turnover. It also explains why peptides cannot be recovered from cells unless they are protected by binding to MHC class I molecules [ref 71]. The rest is simply destroyed before they can be analysed."